ArticleScientific reports2025
Using machine learning to discover DNA metabolism biomarkers that direct prostate cancer treatment.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA metabolism genes play pivotal roles in the regulation of cellular processes that contribute to cancer progression, immune modulation, and therapeutic response in prostate cancer (PC). Understanding the mechanisms by which these genes influence the tumor microenvironment and immune evasion is crucial for identifying prognostic biomarkers and developing targeted therapies. We performed an integrative analysis using transcriptomic data from the TCGA cohort and external validation datasets. Differentially expressed genes (DEGs) were identified using the edgeR algorithm with an FDR < 0.01 and a minimum fold change of 1.5. Gene enrichment analysis was conducted through GO and KEGG pathways to explore the biological significance of DNA metabolism genes in PC. In addition, clustering analyses, machine learning models, and single-cell RNA sequencing (scRNA-seq) were employed to investigate the immune characteristics, prognostic value, and therapeutic relevance of these genes. A total of 536 DEGs were identified across six subtypes of prostate cancer, with key DNA metabolism genes such as POLD2, RAD9A, REV3L, MSH6, and WRNIP1 highlighted as critical players. Gene enrichment analyses revealed that these DEGs were significantly associated with pathways involved in DNA repair, cellular aging, and telomere maintenance. Clustering analysis identified two distinct subgroups (C1 and C2) based on DNA metabolism gene expression, with C1 exhibiting a more aggressive phenotype, higher immune infiltration, and poorer prognosis. Machine learning models, particularly the CoxBoost algorithm, identified 21 key genes contributing to an effective prognostic model. Furthermore, scRNA-seq analysis confirmed the upregulation of DNA metabolism genes in PC cells compared to normal cells. Our findings highlight the importance of DNA metabolism genes in the progression and immune dynamics of PC. These genes not only serve as potential biomarkers for prognosis but also offer promising targets for personalized therapies. The integration of multi-omics data and advanced computational models provides new insights into the molecular underpinnings of PC and holds potential for improving treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.